Cellectis

Historical price data

Cellectis is a French-American biotech leader focused on developing universal, allogeneic CAR T-cell therapies using its proprietary TALEN® gene-editing technology. The company's core strategy is to overcome the manufacturing complexity, high cost, and treatment delays associated with autologous CAR-Ts by creating 'off-the-shelf' products from healthy donor cells. Its most advanced candidate, lasme-cel (UCART22), has shown compelling Phase 1 efficacy and safety in relapsed/refractory B-ALL, triggering the initiation of a pivotal Phase 2 trial with a projected peak sales opportunity of ~$700M. Cellectis sustains its innovation through a strong IP estate and strategic partnerships with companies like Allogene and Servier.

Proprietary TALEN® gene-editing technology and PulseAgile® electroporation system for creating precision-engineered, allogeneic 'off-the-shelf' CAR T-cell therapies.

Cellectis competes with other allogeneic CAR-T developers like Allogene, CRISPR Therapeutics, and Precision BioSciences, as well as dominant autologous CAR-T leaders. Its differentiation lies in the proprietary TALEN® gene-editing system, known for high specificity, and an integrated non-viral manufacturing platform.